Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Adenosine A1 receptor regulates osteoclast formation by altering TRAF6/TAK1 signaling.

He W, Cronstein BN.

Purinergic Signal. 2012 Jun;8(2):327-37. doi: 10.1007/s11302-012-9292-9. Epub 2012 Feb 5.

3.

2-Methoxystypandrone represses RANKL-mediated osteoclastogenesis by down-regulating formation of TRAF6-TAK1 signalling complexes.

Chiou WF, Liao JF, Huang CY, Chen CC.

Br J Pharmacol. 2010 Sep;161(2):321-35. doi: 10.1111/j.1476-5381.2010.00823.x.

4.

Rhinacanthin C Inhibits Osteoclast Differentiation and Bone Resorption: Roles of TRAF6/TAK1/MAPKs/NF-κB/NFATc1 Signaling.

Tomomura M, Suzuki R, Shirataki Y, Sakagami H, Tamura N, Tomomura A.

PLoS One. 2015 Jun 17;10(6):e0130174. doi: 10.1371/journal.pone.0130174. eCollection 2015.

5.

(+)-Vitisin A inhibits osteoclast differentiation by preventing TRAF6 ubiquitination and TRAF6-TAK1 formation to suppress NFATc1 activation.

Chiou WF, Huang YL, Liu YW.

PLoS One. 2014 Feb 18;9(2):e89159. doi: 10.1371/journal.pone.0089159. eCollection 2014.

6.

JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.

Ikeda F, Matsubara T, Tsurukai T, Hata K, Nishimura R, Yoneda T.

J Bone Miner Res. 2008 Jun;23(6):907-14. doi: 10.1359/jbmr.080211.

7.

TAK1 is essential for osteoclast differentiation and is an important modulator of cell death by apoptosis and necroptosis.

Lamothe B, Lai Y, Xie M, Schneider MD, Darnay BG.

Mol Cell Biol. 2013 Feb;33(3):582-95. doi: 10.1128/MCB.01225-12. Epub 2012 Nov 19.

8.

Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways.

Wei ZF, Tong B, Xia YF, Lu Q, Chou GX, Wang ZT, Dai Y.

PLoS One. 2013;8(3):e59171. doi: 10.1371/journal.pone.0059171. Epub 2013 Mar 11.

9.

Regulation of RANKL-induced osteoclastogenesis by TGF-β through molecular interaction between Smad3 and Traf6.

Yasui T, Kadono Y, Nakamura M, Oshima Y, Matsumoto T, Masuda H, Hirose J, Omata Y, Yasuda H, Imamura T, Nakamura K, Tanaka S.

J Bone Miner Res. 2011 Jul;26(7):1447-56. doi: 10.1002/jbmr.357.

10.

Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.

J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242.

11.
12.

Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-kappaB transactivation by RANKL.

Huang H, Ryu J, Ha J, Chang EJ, Kim HJ, Kim HM, Kitamura T, Lee ZH, Kim HH.

Cell Death Differ. 2006 Nov;13(11):1879-91. Epub 2006 Feb 24.

13.

Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.

Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH.

Mol Pharmacol. 2010 Jan;77(1):17-25. doi: 10.1124/mol.109.057877. Epub 2009 Oct 14.

14.

12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.

Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J.

J Bone Miner Res. 2003 Dec;18(12):2159-68.

15.

Rolofylline, an adenosine A1 receptor antagonist, inhibits osteoclast differentiation as an inverse agonist.

He W, Wilder T, Cronstein BN.

Br J Pharmacol. 2013 Nov;170(6):1167-76. doi: 10.1111/bph.12342.

16.

Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.

Koide N, Kondo Y, Odkhuu E, Ulziisaikhan J, Ukaji T, Yokochi T, Umezawa K.

Immunol Lett. 2014 Sep;161(1):31-7. doi: 10.1016/j.imlet.2014.04.006. Epub 2014 May 2.

PMID:
24792671
17.

TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.

Kanazawa K, Kudo A.

J Bone Miner Res. 2005 May;20(5):840-7. Epub 2004 Dec 20.

18.

Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6.

Mizukami J, Takaesu G, Akatsuka H, Sakurai H, Ninomiya-Tsuji J, Matsumoto K, Sakurai N.

Mol Cell Biol. 2002 Feb;22(4):992-1000.

19.

Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation.

Hyeon S, Lee H, Yang Y, Jeong W.

Free Radic Biol Med. 2013 Dec;65:789-99. doi: 10.1016/j.freeradbiomed.2013.08.005. Epub 2013 Aug 14.

PMID:
23954472
20.

Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.

Zhu L, Wei H, Wu Y, Yang S, Xiao L, Zhang J, Peng B.

Int J Biochem Cell Biol. 2012 Jul;44(7):1139-52. doi: 10.1016/j.biocel.2012.04.003. Epub 2012 Apr 12.

PMID:
22521613
Items per page

Supplemental Content

Write to the Help Desk